10x Genomics Dirección
Dirección controles de criterios 3/4
El CEO de 10x Genomics es Serge Saxonov , nombrado en Jul 2012, tiene una permanencia de 12.33 años. compensación anual total es $8.29M, compuesta por 6.6% salario y 93.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 3.32% de las acciones de la empresa, por valor de $57.59M. La antigüedad media del equipo directivo y de la junta directiva es de 2.8 años y 5.4 años, respectivamente.
Información clave
Serge Saxonov
Chief Executive Officer (CEO)
US$8.3m
Compensación total
| Porcentaje del salario del CEO | 6.6% |
| Permanencia del CEO | 12.3yrs |
| Participación del CEO | 3.3% |
| Permanencia media de la dirección | 2.8yrs |
| Promedio de permanencia en la Junta Directiva | 5.4yrs |
Actualizaciones recientes de la dirección
Recent updates
Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts
Nov 01
10x Genomics: Deciphering The Preliminary Q3 Earnings
Oct 12The Price Is Right For 10x Genomics, Inc. (NASDAQ:TXG) Even After Diving 28%
Oct 1110x Genomics Is Still A Long Way From Profitability
Oct 03We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow
Sep 09Investors Still Aren't Entirely Convinced By 10x Genomics, Inc.'s (NASDAQ:TXG) Revenues Despite 30% Price Jump
Aug 1010x Genomics Stock Slips As Illumina Snaps Up Competitor - Tough Times Ahead
Jul 1010x Genomics: Sticking To The Plan To Avoid The Falling The Knife
Jun 21Take Care Before Jumping Onto 10x Genomics, Inc. (NASDAQ:TXG) Even Though It's 26% Cheaper
Jun 1410x Genomics (NASDAQ:TXG) Is In A Strong Position To Grow Its Business
May 21Why We're Not Concerned About 10x Genomics, Inc.'s (NASDAQ:TXG) Share Price
Apr 15Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation
Feb 0510x Genomics: Sales Are Growing At A Rapid Rate, But So Are Expenses
Jan 20Revenues Tell The Story For 10x Genomics, Inc. (NASDAQ:TXG) As Its Stock Soars 31%
Dec 22We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely
Nov 03Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation
Aug 04Why Investors Shouldn't Be Surprised By 10x Genomics, Inc.'s (NASDAQ:TXG) P/S
Jun 04At US$52.43, Is 10x Genomics, Inc. (NASDAQ:TXG) Worth Looking At Closely?
Apr 2910x Genomics, Inc. (NASDAQ:TXG) Shares Could Be 28% Below Their Intrinsic Value Estimate
Mar 24We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow
Feb 02Is Now The Time To Look At Buying 10x Genomics, Inc. (NASDAQ:TXG)?
Jan 12An Intrinsic Calculation For 10x Genomics, Inc. (NASDAQ:TXG) Suggests It's 39% Undervalued
Dec 22Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$183m |
| Jun 30 2024 | n/a | n/a | -US$240m |
| Mar 31 2024 | n/a | n/a | -US$264m |
| Dec 31 2023 | US$8m | US$545k | -US$255m |
| Sep 30 2023 | n/a | n/a | -US$223m |
| Jun 30 2023 | n/a | n/a | -US$172m |
| Mar 31 2023 | n/a | n/a | -US$174m |
| Dec 31 2022 | US$19m | US$504k | -US$166m |
| Sep 30 2022 | n/a | n/a | -US$167m |
| Jun 30 2022 | n/a | n/a | -US$142m |
| Mar 31 2022 | n/a | n/a | -US$89m |
| Dec 31 2021 | US$12m | US$430k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$455m |
| Jun 30 2021 | n/a | n/a | -US$504m |
| Mar 31 2021 | n/a | n/a | -US$533m |
| Dec 31 2020 | US$11m | US$400k | -US$543m |
| Sep 30 2020 | n/a | n/a | -US$134m |
| Jun 30 2020 | n/a | n/a | -US$78m |
| Mar 31 2020 | n/a | n/a | -US$49m |
| Dec 31 2019 | US$2m | US$394k | -US$31m |
| Sep 30 2019 | n/a | n/a | -US$100m |
| Jun 30 2019 | n/a | n/a | -US$105m |
| Mar 31 2019 | n/a | n/a | -US$105m |
| Dec 31 2018 | US$1m | US$366k | -US$112m |
Compensación vs. Mercado: La compensación total de Serge($USD8.29M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD5.50M).
Compensación vs. Ingresos: La compensación de Serge ha sido consistente con los resultados de la empresa en el último año.
CEO
Serge Saxonov (47 yo)
12.3yrs
Permanencia
US$8,286,050
Compensación
Dr. Serge Saxonov, Ph D, Co-Founded 10X Genomics, Inc. and has been its Chief Executive Officer and Director since July 2012. Prior to 10x Genomics, Dr. Saxonov was Vice President of Applications at Quanta...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 12.3yrs | US$8.29m | 3.32% $ 57.6m | |
| Co-Founder | 12.3yrs | US$4.43m | 2.68% $ 46.3m | |
| Chief Legal Officer | 7.3yrs | US$3.88m | 0.12% $ 2.0m | |
| CFO, Treasurer | less than a year | sin datos | sin datos | |
| Chief of Global Operations | less than a year | sin datos | sin datos | |
| Founding Scientist & CTO | 2.8yrs | sin datos | sin datos | |
| Chief Information Officer | less than a year | sin datos | sin datos | |
| Manager of Investor Relations & Strategic Finance | no data | sin datos | sin datos | |
| Chief People Officer | 3.8yrs | sin datos | sin datos | |
| Chief Commercial Officer | less than a year | sin datos | sin datos | |
| Associate Director of Product Management | no data | sin datos | sin datos |
2.8yrs
Permanencia media
48.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de TXG se considera experimentado (2.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 12.3yrs | US$8.29m | 3.32% $ 57.6m | |
| Co-Founder | 12.3yrs | US$4.43m | 2.68% $ 46.3m | |
| Independent Director | 4.7yrs | US$338.71k | 0.0038% $ 66.0k | |
| Independent Chairman | 11.3yrs | US$403.59k | 2.02% $ 34.9m | |
| Independent Director | 5.3yrs | US$336.39k | 0.0038% $ 66.0k | |
| Director | less than a year | sin datos | sin datos | |
| Independent Director | 5.6yrs | US$346.39k | 0.029% $ 507.2k | |
| Director | less than a year | sin datos | sin datos |
5.4yrs
Permanencia media
52yo
Promedio de edad
Junta con experiencia: La junta directiva de TXG se considera experimentada (5.4 años de antigüedad promedio).